Warner Chilcott
As of the edition of 20 October 2026, Warner Chilcott runs 10 drugs, 9 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 9 |
| Went quiet | 1 |
| Total | 10 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Estradiol | Ends 2032 (patent) | 6 |
| Furosemide | none listed | 2 |
| Fluoxetine | none listed | 1 |
| Mesalamine | Ends 2027 (patent) | 12 |
| Cyanocobalamin | none listed | 0 |
| Risedronic acid | none listed | 2 |
| Nystatin | none listed | 0 |
| Estradiol acetate | none listed | 1 |
| Pyrithione | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Urinary and reproductive: 4 trials led
- Mental health: 3 trials led